Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock Rating Upgraded by The Goldman Sachs Group

Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a report released on Thursday, The Fly reports.

CHGCY stock opened at $16.53 on Thursday. The stock has a 50-day moving average price of $16.81 and a two-hundred day moving average price of $18.09. Chugai Pharmaceutical has a 12-month low of $15.08 and a 12-month high of $28.56.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan.

Read More: Pattern Day Trader

The Fly logo

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.